CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California.
The abstracts are currently available on the AACR meeting website. The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
Poster Presentation Details:
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high impact cancers. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
CONTACT:
Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190
info@actuatetherapeutics.com
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation…
PARSIPPANY, N.J., April 11, 2025 /PRNewswire/ -- Diagnostica Stago, Inc., a global leader in hemostasis…
The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities…
BRIDGEWATER, N.J., April 11, 2025 /PRNewswire/ -- Hamamatsu Photonics, a global leader in whole slide…
NASHVILLE, Tenn., April 11, 2025 /PRNewswire/ -- Entering its 15th year, ProviderTrust continues to lead…
Through the Technology in Space Prize, two startups will receive more than $650,000 in total…